IDiyas

For the Inventor, By the Inventor

Frederiksberg, Denmark

Nathalie Schlienger

USPTO Granted Patents = 15

 

Average Co-Inventor Count = 1.9

ph-index = 11

Forward Citations = 265(Granted Patents)


Company Filing History:

goldMedal15 out of 92 
 
Acadia Pharmaceuticals Inc.
 patents

Years Active: 2005-2012

Loading Chart...
Loading Chart...
15 patents (USPTO):Explore Patents
1. 8236960 - Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms (2012-08-07),
2. 7923564 - Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms (2011-04-12),
3. 7868176 - Salts of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-y1)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and their preparation (2011-01-11),
4. 7790899 - Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms (2010-09-07),
5. 7732615 - N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms (2010-06-08),
6. 7727999 - Spiroazacyclic compounds as monoamine receptor modulators (2010-06-01),
7. 7585877 - Aminophenyl derivatives as selective androgen receptor modulators (2009-09-08),
8. 7538222 - N-substituted piperidine derivatives as serotonin receptor agents (2009-05-26),
9. 7511053 - Spiroazacyclic compounds as monoamine receptor modulators (2009-03-31),
10. 7476682 - N-substituted piperidine derivatives as serotonin receptor agents (2009-01-13),
11. 7402590 - Spiroazacyclic compounds as monoamine receptor modulators (2008-07-22),
12. 7351707 - Spiroazacyclic compounds as monoamine receptor modulators (2008-04-01),
13. 7268232 - Androgen receptor modulators and method of treating disease using the same (2007-09-11),
14. 7217719 - Spiroazacyclic compounds as monoamine receptor modulators (2007-05-15),
15. 6911452 - Spiroazacyclic compounds as monoamine receptor modulators (2005-06-28),

Title: Nathalie Schlienger: A Trailblazing Innovator from Frederiksberg, Denmark

Introduction:

Nathalie Schlienger, a prolific inventor based in Frederiksberg, Denmark, has gained widespread recognition for her dedication to innovation and exceptional problem-solving skills. With a remarkable portfolio of 15 patents, Schlienger continues to inspire aspiring inventors and researchers worldwide.

Latest Patents:

Schlienger's latest patent titled "Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy) phenylmethyl)carbamide and its tartrate salt and crystalline forms" showcases her expertise in synthesizing complex compounds and discovering novel crystalline forms. The patent discloses innovative methods for synthesizing the compound and its hemi-tartrate salt, along with various polymorphs and solvates.

Career Highlights:

Currently affiliated with Acadia Pharmaceuticals Inc., Schlienger has significantly contributed to the research and development of novel pharmaceutical compounds. Her work exemplifies a blend of scientific rigor, creativity, and a relentless pursuit of perfection, leading to groundbreaking innovations in the healthcare industry.

Collaborations:

Schlienger has collaborated with esteemed colleagues such as Mikkel Boas Thygesen and Bo-Ragnar Tolf in her endeavors. These collaborations have not only enhanced the quality of her research but have also fostered a culture of innovation and knowledge-sharing within the scientific community.

Conclusion:

In conclusion, Nathalie Schlienger's innovative spirit and remarkable achievements have solidified her reputation as a prominent inventor in Denmark and beyond. Her unwavering dedication to pushing the boundaries of scientific discovery continues to shape the landscape of modern innovation, paving the way for future generations of inventors to follow in her footsteps.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…